Dr. Ahmet Özen, M.D., who is the Director of the Istanbul Jeffrey Modell Foundation Center, is also a Professor and Chief of the Pediatric Allergy and Immunology Division at Marmara University. Graduating from Marmara University School of Medicine, he completed his residency at Yeditepe University in the field of Allergy and Immunology. He got postdoctoral fellowship in NIH. Dr. Özen established a national network for monogenic Inflammatory Bowel Disease (mIBD) in Türkiye. His discovery of CHAPLE disease has paved the way for FDA's approval of pozelimab for patients with CHAPLE disease. He is the founder of the Marmara University Işıl Berat Barlan Center for Translational Medicine and contributes to the NIAID-MENAT Strategy for Enhanced Research Engagement Program.